Entellus Medical, Inc. (ENTL) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Entellus Medical, Inc. (NASDAQ:ENTL) from a sell rating to a buy rating in a report issued on Monday morning. They currently have $23.00 price objective on the medical technology company’s stock.

According to Zacks, “Entellus Medical, Inc. is a medical technology company. It is engaged in the designing, development and commercialization of products for the treatment of chronic sinusitis. The company operates primarily in the United States and Canada. Entellus Medical, Inc. is headquartered in Plymouth, Minnesota. “

Other equities research analysts have also issued reports about the stock. Piper Jaffray Companies reiterated a buy rating on shares of Entellus Medical in a report on Wednesday, July 12th. BidaskClub lowered shares of Entellus Medical from a strong-buy rating to a buy rating in a report on Saturday, July 8th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Entellus Medical has an average rating of Hold and an average price target of $22.00.

Entellus Medical (ENTL) traded down 2.48% during trading on Monday, reaching $19.26. 109,624 shares of the company’s stock traded hands. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $20.69. The company has a 50 day moving average price of $18.25 and a 200-day moving average price of $18.25. The company’s market cap is $488.65 million.

Entellus Medical (NASDAQ:ENTL) last released its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.03). The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. Entellus Medical’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.27) earnings per share. On average, equities research analysts forecast that Entellus Medical will post ($1.61) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Entellus Medical, Inc. (ENTL) Upgraded at Zacks Investment Research” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/10/12/entellus-medical-inc-entl-upgraded-at-zacks-investment-research.html.

In other news, VP Timothy B. Petrick sold 2,000 shares of the firm’s stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $18.00, for a total value of $36,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Brian E. Farley sold 40,000 shares of the firm’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $19.78, for a total transaction of $791,200.00. The disclosure for this sale can be found here. Insiders sold a total of 79,650 shares of company stock worth $1,510,252 over the last 90 days. Company insiders own 7.70% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in shares of Entellus Medical by 53.8% in the 1st quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after purchasing an additional 2,594 shares in the last quarter. Nationwide Fund Advisors raised its holdings in shares of Entellus Medical by 61.7% in the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 2,635 shares in the last quarter. First Mercantile Trust Co. raised its holdings in shares of Entellus Medical by 45.3% in the 2nd quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock valued at $136,000 after purchasing an additional 2,557 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in shares of Entellus Medical by 5.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after purchasing an additional 573 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Entellus Medical by 61.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock valued at $196,000 after purchasing an additional 4,533 shares in the last quarter. Institutional investors and hedge funds own 70.27% of the company’s stock.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Get a free copy of the Zacks research report on Entellus Medical (ENTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply